<DOC>
	<DOCNO>NCT00825643</DOCNO>
	<brief_summary>This study conduct Europe , North America Asia . The aim observational study evaluate safety effectiveness use Levemir速 daily combination oral antidiabetic drug type 2 diabetic 24 week normal clinical practice . Data NN304-3573 study ( NCT00740519 ) pool data study report together final study report study .</brief_summary>
	<brief_title>Observational Study Evaluate Safety Levemir速 Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<criteria>After participate physician 's decision make initiate oncedaily Levemir速 therapy , patient Type 2 diabetes currently treat diet , exercise one OADs offer participate Current treatment insulin Known suspect allergy Levemir速 excipients Children age 6 year Females childbearing potential pregnant , breastfeed intend become pregnant within next 6 month use adequate contraceptive method ( contraceptive measure require local law practice )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>